5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers-Reference-Cited by-同舟云学术

5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers

Published:2016-10-18 Issue:1 Volume:4 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Van Der Kraak Lauren,Goel Gaurav,Ramanan Krishnaveni,Kaltenmeier Christof,Zhang Lin,Normolle Daniel P.,Freeman Gordon J.,Tang Daolin,Nason Katie S.,Davison Jon M.,Luketich James D.,Dhupar Rajeev,Lotze Michael T.

Funder

National Cancer Institute (US)

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-016-0163-8.pdf

Reference34 articles.

1. Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21 Suppl 7:vii252–61. doi: 10.1093/annonc/mdq453 .

2. Ilson DH. Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res. 2008;2(2):85–92.

3. Ghosn M, Kourie HR, Abdayem P, et al. Anal cancer treatment: current status and future perspectives. World J Gastroenterol. 2015;21(8):2294–302. doi: 10.3748/wjg.v21.i8.2294 .

4. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8. doi: 10.1038/nrc1074 .

5. Luo M, Fu L. The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. Oncotarget. 2016;7(20):29794–803. 10.18632/oncotarget.7631.

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PD-1 inhibitor combined with Docetaxel exerts synergistic anti-prostate cancer effect in mice by down-regulating the expression of PI3K/AKT/NFKB-P65/PD-L1 signaling pathway;Cancer Biomarkers;2024-05-28

2. Doxorubicin induces deglycosylation of cancer cell‐intrinsic PD‐1 by NGLY1;FEBS Letters;2024-05-23

3. Impact of Doxorubicin and Docetaxel on Immune Checkpoint Expression in Colorectal Cancer: Insights into Chemotherapy Resistance Mechanisms;Biochemical Genetics;2024-05-09

4. Combined Metronomic Chemo-immunotherapy (CMCI) in Head and Neck Cancers–An Experience from a Developing Country;Indian Journal of Surgical Oncology;2024-02-20

5. Targeting paraptosis in cancer: opportunities and challenges;Cancer Gene Therapy;2024-01-04